Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria

Introduction: Efficacious vaccines that prevent human papillomavirus (HPV) infection, the recognized cause of cervical cancer, are now available. However, in sub-Saharan Africa, immune-modulating infections such as helminths and malaria may affect immunogenicity to the HPV vaccine. This study aimed...

Full description

Saved in:
Bibliographic Details
Main Authors: Miriam Nakalembe, Cecily Banura, Proscovia Bazanye Namujju, Florence Maureen Mirembe
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2015-02-01
Series:Journal of Infection in Developing Countries
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/5719
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850148836893261824
author Miriam Nakalembe
Cecily Banura
Proscovia Bazanye Namujju
Florence Maureen Mirembe
author_facet Miriam Nakalembe
Cecily Banura
Proscovia Bazanye Namujju
Florence Maureen Mirembe
author_sort Miriam Nakalembe
collection DOAJ
description Introduction: Efficacious vaccines that prevent human papillomavirus (HPV) infection, the recognized cause of cervical cancer, are now available. However, in sub-Saharan Africa, immune-modulating infections such as helminths and malaria may affect immunogenicity to the HPV vaccine. This study aimed to evaluate the effect of helminth infections and exposure to malaria on the immune response to the bivalent HPV-16/18 vaccine. Methodology:AS04-adjuvanted HPV-16/18 vaccinated students between 10 and 16 years of age from western Uganda, at 18 months-post vaccination were followed up for six months. After consent was obtained, demographic data, blood, and stool samples were collected. Multiplex HPV serology technology was used to determine HPV-16/18 antibody levels expressed as median fluorescent intensity (MFI). The malaria antibody immunoassay test was used to detect antibodies to malaria parasites. The Kato-Katz method was used to detect the presence of helminths. HPV-16/18 antibody levels among students exposed to malaria or helminths were compared with those who were not exposed using the Student’s t-test. Results: A total of 211 students participated in the study. There was no difference between MFI levels to HPV-16/18 antibodies at 18- and 24-month follow-ups among students who were positive and negative to malaria or helminth exposure. There was an increase in HPV-18 MFI antibody levels at month 24 among the students who were positive for malaria at enrolment (p = 0.05). Conclusions:Immune-modulating parasites (malaria/helminths) were not associated with reduced immune response to the bivalent HPV-16/18 vaccine. The data may support the use of this vaccine in sub-Saharan Africa.
format Article
id doaj-art-f27f8c3d053441268e9e38f23498383a
institution OA Journals
issn 1972-2680
language English
publishDate 2015-02-01
publisher The Journal of Infection in Developing Countries
record_format Article
series Journal of Infection in Developing Countries
spelling doaj-art-f27f8c3d053441268e9e38f23498383a2025-08-20T02:27:09ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802015-02-0190210.3855/jidc.5719Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malariaMiriam Nakalembe0Cecily Banura1Proscovia Bazanye Namujju2Florence Maureen Mirembe3Makerere University, Kampala, UgandaMakerere University, Kampala, UgandaNational Institute for Health and Welfare, Oulu, FinlandMakerere University, Kampala, UgandaIntroduction: Efficacious vaccines that prevent human papillomavirus (HPV) infection, the recognized cause of cervical cancer, are now available. However, in sub-Saharan Africa, immune-modulating infections such as helminths and malaria may affect immunogenicity to the HPV vaccine. This study aimed to evaluate the effect of helminth infections and exposure to malaria on the immune response to the bivalent HPV-16/18 vaccine. Methodology:AS04-adjuvanted HPV-16/18 vaccinated students between 10 and 16 years of age from western Uganda, at 18 months-post vaccination were followed up for six months. After consent was obtained, demographic data, blood, and stool samples were collected. Multiplex HPV serology technology was used to determine HPV-16/18 antibody levels expressed as median fluorescent intensity (MFI). The malaria antibody immunoassay test was used to detect antibodies to malaria parasites. The Kato-Katz method was used to detect the presence of helminths. HPV-16/18 antibody levels among students exposed to malaria or helminths were compared with those who were not exposed using the Student’s t-test. Results: A total of 211 students participated in the study. There was no difference between MFI levels to HPV-16/18 antibodies at 18- and 24-month follow-ups among students who were positive and negative to malaria or helminth exposure. There was an increase in HPV-18 MFI antibody levels at month 24 among the students who were positive for malaria at enrolment (p = 0.05). Conclusions:Immune-modulating parasites (malaria/helminths) were not associated with reduced immune response to the bivalent HPV-16/18 vaccine. The data may support the use of this vaccine in sub-Saharan Africa. https://jidc.org/index.php/journal/article/view/5719HPV vaccineimmunogenicityhelminthsmalariaUganda
spellingShingle Miriam Nakalembe
Cecily Banura
Proscovia Bazanye Namujju
Florence Maureen Mirembe
Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria
Journal of Infection in Developing Countries
HPV vaccine
immunogenicity
helminths
malaria
Uganda
title Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria
title_full Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria
title_fullStr Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria
title_full_unstemmed Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria
title_short Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria
title_sort immunogenicity to the bivalent hpv 16 18 vaccine among adolescent african students exposed to helminths and malaria
topic HPV vaccine
immunogenicity
helminths
malaria
Uganda
url https://jidc.org/index.php/journal/article/view/5719
work_keys_str_mv AT miriamnakalembe immunogenicitytothebivalenthpv1618vaccineamongadolescentafricanstudentsexposedtohelminthsandmalaria
AT cecilybanura immunogenicitytothebivalenthpv1618vaccineamongadolescentafricanstudentsexposedtohelminthsandmalaria
AT proscoviabazanyenamujju immunogenicitytothebivalenthpv1618vaccineamongadolescentafricanstudentsexposedtohelminthsandmalaria
AT florencemaureenmirembe immunogenicitytothebivalenthpv1618vaccineamongadolescentafricanstudentsexposedtohelminthsandmalaria